|
Thomas Q. Garvey III, M.D. is a practicing gastroenterologist in Rockville, Maryland. He was formerly Supervisory Medical Officer in FDA’s Division of Cardio-Renal Drug Products (HFD-110). His consulting firm, Garvey Associates, Inc., which is in its 25th year, is engaged primarily in designing and analyzing clinical trials and programs of clinical trials for drugs, biologics, and devices.
Garvey Associates, Inc. has been responsible for development and composition of many successful NDAs for gastroenterologic (e.g., histamine H2 inhibitors, proton pump blockers, bile acids), cardiovascular (e.g., antihypertensives, antiarrhythmics) endocrinologic (e.g., hypolipidemics, oral hypoglycemics), oncologic (e.g., cytolytics, growth factor antagonists), neurologic (e.g., drugs for attention deficit hyperactivity disorder [ADHD] and migraine headaches); urologic (e.g., drugs for overactive bladder) and other classes of drugs.
Current projects include NDA development programs for a pancreatic enzyme replacement, an inhaled insulin, a parenteral anticoagulant, a drug-device anti-tumor combination therapy and an ADHD drug, and an OTC switch for a gastrointestinal drug. Dr. Garvey received his B.A. from Harvard College, his M.D. from New York University, his training in internal medicine at Roosevelt Hospital in New York and Georgetown University Hospital in Washington, DC, and his training in Gastroenterology at the Massachusetts General Hospital in Boston. He spent many years in basic research in the Laboratory of Biochemistry in the National Cancer Institute and in the Digestive Disease Branch of the National Institute of Diabetes, Digestive and Kidney Diseases. | 